摘要
胼胝体是连接大脑左右半球最大的连合纤维。最新研究表明,在这种白质纤维微观结构中发现的各种异常是阿尔茨海默氏病(AD)的早期病理症状。然而,人们对AD发病过程中这些异常组织的特征,以及他它们是如何演化的了解甚少。本文中,我们测量体内磁共振横向弛豫时间(T2)来纵向监测AD小鼠模型胼胝体组织完整性的改变以及髓鞘形成及脱髓鞘过程相关的异常变化。最引人注目是,与相同年龄的野生型小鼠相比,10、14、16以及18个月大的小鼠胼胝体T2值显著变长。相反,胼胝体周围灰质区如在皮层和海马区,T2 值却明显减小。组织学分析显示了胼胝体髓鞘的脱失、胶质细胞的增生和淀粉样斑块的沉积。我们的研究结果表明,脱髓鞘和炎症可能使AD弛豫时间延长。据我们所知,这是第一次体内研究T2 值来评估Tg2576转基因小鼠模型胼胝体随着年龄增长的微观结构的变化,证明了利用T2无创性检测胼胝体的组织完整性 的有效性,这可能是疾病的早期症状。
关键词: 阿尔茨海默病,T2弛豫时间,胼胝体,髓鞘脱失,胶质细胞增生,纵向研究,Tg2576小鼠模型。
Current Alzheimer Research
Title:In Vivo Longitudinal Monitoring of Changes in the Corpus Callosum Integrity During Disease Progression in a Mouse Model of Alzheimer’s Disease
Volume: 12 Issue: 10
Author(s): F. Kara, C. Höfling, S. Roßner, R. Schliebs, A. Van der Linden, H.J.M. Groot and A. Alia
Affiliation:
关键词: 阿尔茨海默病,T2弛豫时间,胼胝体,髓鞘脱失,胶质细胞增生,纵向研究,Tg2576小鼠模型。
摘要: The corpus callosum is the largest commissural fiber connecting left and right hemisphere of the brain. Emerging evidence suggests that a variety of abnormalities detected in the microstructure of this white matter fiber can be an early event in Alzheimer's disease (AD) pathology. However, little is known about tissue characteristics of these abnormalities and how these abnormalities evolve during AD progression. In this study, we measured in vivo magnetic resonance transverse relaxation times (T2) to longitudinally monitor changes in tissue integrity and abnormalities related to myelination and demyelination processes in corpus callosum of AD mouse models. The most striking finding of our study was a significant elongation of T2 values in the corpus callosum at 10, 14, 16 and 18 months of age compared to age-matched wild-type mice. In contrast, the gray matter regions surrounding the corpus callosum, such as the cortex and hippocampus, showed a significant T2 decrease compared to wild-type mice. Histological analyses clearly revealed demyelination, gliosis and amyloid-plaque deposition in the corpus callosum. Our results suggest that demyelinating and inflammatory pathology may result in prolonged relaxation time during AD progression. To our knowledge, this is the first in vivo T2 study assessing the microstructural changes with age in the corpus callosum of the Tg2576 mouse model and it demonstrates the application of T2 measurement to noninvasively detect tissue integrity of the corpus callosum, which can be an early event in disease progression.
Export Options
About this article
Cite this article as:
F. Kara, C. Höfling, S. Roßner, R. Schliebs, A. Van der Linden, H.J.M. Groot and A. Alia , In Vivo Longitudinal Monitoring of Changes in the Corpus Callosum Integrity During Disease Progression in a Mouse Model of Alzheimer’s Disease, Current Alzheimer Research 2015; 12 (10) . https://dx.doi.org/10.2174/1567205012666151027123728
DOI https://dx.doi.org/10.2174/1567205012666151027123728 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alpha-7 Nicotinic Receptors in Nervous System Disorders: From Function to Therapeutic Perspectives
Central Nervous System Agents in Medicinal Chemistry The Effects of Aqueous Extract of Apium Graveolens on Brain Tissues Oxidative Damage in Pentylenetetrazole-induced Seizures Model in Rat
Current Nutrition & Food Science Definition of Genes and Paths Involved in Alzheimers Disease: Using Gene Expression Profiles and Chemical Genetics at the Mouse Brain Level
Current Genomics Basic Pharmacology of NMDA Receptors
Current Pharmaceutical Design Menthone Semicarbazides and Thiosemicarbazides as Anticonvulsant Agents
Medicinal Chemistry [General Articles] Cannabinoids: Mechanisms and Therapeutic Applications in the CNS
Current Medicinal Chemistry Microglia and Neuropathic Pain
CNS & Neurological Disorders - Drug Targets The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment
CNS & Neurological Disorders - Drug Targets Metastasis-Associated Protein S100A4: Spotlight on its Role in Cell Migration
Current Cancer Drug Targets Medication-precipitated Seizure in Psychiatric Patients: Typical vs. Atypical Antipsychotics
Current Psychopharmacology (Section A: Molecular, Structural, and Cellular Biology of Drug Transporters) The Role of MDR1 Genetic Polymorphisms in Interindividual Variability in P-glycoprotein Expression and Function
Current Drug Metabolism Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors
Current Pharmaceutical Design Recent Advances in the Treatment of Amyotrophic Lateral Sclerosis. Emphasis on Kynurenine Pathway Inhibitors
Central Nervous System Agents in Medicinal Chemistry Serum Thiol-Disulphide Levels in Epileptic Pediatric Patients
Combinatorial Chemistry & High Throughput Screening Pharmacogenetics and Anaesthesiology
Current Pharmacogenomics Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors
Current Topics in Medicinal Chemistry Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design The GABA Shunt: An Attractive and Potential Therapeutic Target in the Treatment of Epileptic Disorders
Current Drug Metabolism Research Review: Childhood Maltreatment and Executive Functioning During Adolescence
Adolescent Psychiatry In Silico Dynamic Molecular Interaction Networks for the Discovery of New Therapeutic Targets
Current Pharmaceutical Design